v3.25.1
Segment Reporting - Summary of Reconciled Expense of Consolidated Statement of Operations and Comprehensive Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Collaboration revenue $ 5,952 $ 5,050
Research and development:    
Research and development expense 21,626 25,534
General and administrative:    
Interest income 2,692 2,439
Net loss (18,834) (25,016)
Stock-based compensation expense 2,692 3,224
Depreciation and amortization expense 827 835
The Segment    
Segment Reporting Information [Line Items]    
Collaboration revenue 5,952 5,050
General and administrative:    
Personnel expenses 2,927 2,543
External expenses 2,072 2,574
Facilities and IT related expenses, net of sublease income 1,877 2,715
Other expenses 3,528 4,063
Interest income 2,692 2,439
Net loss (18,834) (25,016)
Stock-based compensation expense 2,700 3,200
Depreciation and amortization expense 800 800
Personnel expenses | The Segment    
Research and development:    
Research and development expense 6,344 6,287
FHD-286 | The Segment    
Research and development:    
Research and development expense 991 3,526
Lilly partnered programs | The Segment    
Research and development:    
Research and development expense 4,625 3,886
Proprietary programs | The Segment    
Research and development:    
Research and development expense 3,447 5,286
Research and development operating and administrative costs | The Segment    
Research and development:    
Research and development expense $ 1,667 $ 1,625